



Effective Date:
Monday, January 13, 2020

Test Updates

Immediate Action - Modified

Updated November 22, 2019 - The following tests were removed from this Test Update Notification:
8043B, 8092FL, 8092SP, 8092TI and 8092U

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, January 13, 2020

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.



Effective Date:
Monday, January 13, 2020

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
54151B	Brompheniramine Confirmation (DUID/DRE), Blood			•	•				
54150U	Brompheniramine Confirmation (Qualitative) (DUID/DRE), Urine			•	•				
52245B	Brompheniramine Confirmation, Blood			•	•				
5463B	Brompheniramine Confirmation, Blood			•	•				
52245SP	Brompheniramine Confirmation, Serum/Plasma			•	•				
52245U	Brompheniramine Confirmation, Urine			•	•				
9118B	Brompheniramine Screen, Blood			•	•				
0770B	Brompheniramine, Blood			•	•				
0770SP	Brompheniramine, Serum/Plasma			•	•				
0770U	Brompheniramine, Urine			•	•				
54211U	Bupivacaine Confirmation (Qualitative) (DUID/DRE), Urine				•				
52011B	Bupivacaine Confirmation, Blood			•	•				
52011SP	Bupivacaine Confirmation, Serum/Plasma			•	•				
52011U	Bupivacaine Confirmation, Urine				•				
0800B	Bupivacaine, Blood			•	•				
0800SP	Bupivacaine, Serum/Plasma			•	•				
0800U	Bupivacaine, Urine				•				
8152B	DUID/DRE Expanded Drug Screen Add-On ProofPOSITIVE®, Blood (Forensic)			•	•	•			
8075U	DUID/DRE Expanded Drug Screen Add-On, Urine (Forensic)			•		•			
52493U	Designer Benzodiazepines Confirmation (Qualitative), Urine	•				•			
52493B	Designer Benzodiazepines Confirmation, Blood					•			
52493SP	Designer Benzodiazepines Confirmation, Serum/Plasma				•	•			
54173B	Doxylamine Confirmation (DUID/DRE), Blood			•	•				
54171U	Doxylamine Confirmation (Qualitative) (DUID/DRE), Urine			•	•				
52285B	Doxylamine Confirmation, Blood			•	•				
5510B	Doxylamine Confirmation, Blood			•	•				
52285SP	Doxylamine Confirmation, Serum/Plasma			•	•				
5510SP	Doxylamine Confirmation, Serum/Plasma			•	•				
52285U	Doxylamine Confirmation, Urine			•	•				
9163B	Doxylamine Screen, Blood			•	•				



Effective Date:
Monday, January 13, 2020

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
9163SP	Doxylamine Screen, Serum/Plasma			•	•				
1817B	Doxylamine, Blood			•	•				
1817SP	Doxylamine, Serum/Plasma			•	•				
1817U	Doxylamine, Urine			•	•				
8098B	Drug Screen (GC/MS), Blood					•			
8098SP	Drug Screen (GC/MS), Serum/Plasma			•		•			
8098U	Drug Screen (GC/MS), Urine			•		•			
1876B	Drug Screen - Expanded, Blood			•	•	•			
1876FL	Drug Screen - Expanded, Fluid		•	•		•			
1876SP	Drug Screen - Expanded, Serum/Plasma			•	•	•			
1876U	Drug Screen - Expanded, Urine			•	•	•			
90023B	Expanded Drug Screen (DUID/DRE), Blood (Forensic) (CSA)			•					
1860B	GC/MS Drug Screen (Acid/Neutral), Blood (Forensic)			•					
10053U	GC/MS Drug Screen, Urine (CSA)			•		•			
8758B	Hallucinogens Screen, Blood			•					
8758SP	Hallucinogens Screen, Serum/Plasma			•					
8758U	Hallucinogens Screen, Urine			•					
54010B	LSD Confirmation (DUID/DRE), Blood			•					
54010U	LSD Confirmation (Qualitative) (DUID/DRE), Urine			•	•				
52065B	LSD Confirmation, Blood			•					
5811B	LSD Confirmation, Blood			•					
52065SP	LSD Confirmation, Serum/Plasma			•	•				
5811SP	LSD Confirmation, Serum/Plasma			•	•				
52065U	LSD Confirmation, Urine			•	•				
5811U	LSD Confirmation, Urine			•	•				
2541B	LSD Screen, Blood			•					
2541SP	LSD Screen, Serum/Plasma			•	•				
2541U	LSD Screen, Urine			•	•				
2540B	LSD Trace Analysis, Blood			•					
2540SP	LSD Trace Analysis, Serum/Plasma			•	•				
2540U	LSD Trace Analysis, Urine			•	•				
52076B	Methocarbamol and Guaifenesin Confirmation, Blood	•			•	•			



Effective Date:
Monday, January 13, 2020

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
52076FL	Methocarbamol and Guaifenesin Confirmation, Fluid	•				•			
52076SP	Methocarbamol and Guaifenesin Confirmation, Serum/Plasma	•				•			
52076TI	Methocarbamol and Guaifenesin Confirmation, Tissue	•				•			
90034B	NPS Comprehensive Screen, Blood (CSA) - Public Health			•		•			
90034U	NPS Comprehensive Screen, Urine (CSA) - Public Health					•			
52088FL	Nifedipine Confirmation, Fluid			•					
52088TI	Nifedipine Confirmation, Tissue			•					
10101U	Novel Psychoactive Substances (NPS) (Qualitative), Urine (CSA)								•
8210B	Novel Psychoactive Substances (NPS) Screen 2, Blood					•			
8210SP	Novel Psychoactive Substances (NPS) Screen 2, Serum/Plasma					•			
8210U	Novel Psychoactive Substances (NPS) Screen 2, Urine					•			
90000U	Opiates Screen, Urine (CSA)					•			
52389B	Phenethylamines Confirmation 2 (Qualitative), Blood				•	•			
52389SP	Phenethylamines Confirmation 2 (Qualitative), Serum/Plasma					•			
52389U	Phenethylamines Confirmation 2 (Qualitative), Urine					•			
54182B	Pheniramine Confirmation (DUID/DRE), Blood				•				
54181U	Pheniramine Confirmation (Qualitative) (DUID/DRE), Urine			•	•				
52291B	Pheniramine Confirmation, Blood				•				
52291SP	Pheniramine Confirmation, Serum/Plasma			•	•				
52291U	Pheniramine Confirmation, Urine			•	•				
3560B	Pheniramine, Blood				•				
8063B	Postmortem, Basic to Expanded Upgrade, Blood (Forensic)			•		•			
8063FL	Postmortem, Basic to Expanded Upgrade, Fluid (Forensic)			•					
8063SP	Postmortem, Basic to Expanded Upgrade, Serum/Plasma (Forensic)					•			
8063TI	Postmortem, Basic to Expanded Upgrade, Tissue (Forensic)			•					
8063U	Postmortem, Basic to Expanded Upgrade, Urine (Forensic)			•		•			
8042B	Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood (Forensic)			•		•			



Effective Date:

Monday, January 13, 2020

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
10052B	Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)			•		•			
8057B	Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood - University of MI (CSA)			•		•			
8062B	Postmortem, Expanded w/o Alcohol, Blood (Forensic)			•		•			
8062FL	Postmortem, Expanded w/o Alcohol, Fluid (Forensic)			•					
8062TI	Postmortem, Expanded w/o Alcohol, Tissue (Forensic)			•					
8062U	Postmortem, Expanded w/o Alcohol, Urine (Forensic)			•		•			
8054B	Postmortem, Expanded with NPS, Blood			•		•			
8052B	Postmortem, Expanded, Blood (Forensic)			•		•			
90025B	Postmortem, Expanded, Blood (Forensic) (CSA)			•		•			
8052FL	Postmortem, Expanded, Fluid (Forensic)			•					
8052SP	Postmortem, Expanded, Serum/Plasma (Forensic)			•		•			
8052TI	Postmortem, Expanded, Tissue (Forensic)			•					
8052U	Postmortem, Expanded, Urine (Forensic)			•		•			
39052B	Postmortem, Expanded-II, Blood (Forensic) (SSA)			•		•			
39042B	Postmortem, Expanded-II, with Vitreous Alcohol Confirmation, Blood (Forensic) (SSA)			•		•			
10092B	Postmortem, Expert w/Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)		•	•		•			
10151B	Postmortem, Expert w/Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)		•			•			
8092B	Postmortem, Expert, Blood (Forensic)					•			
4177B	Postmortem, SUIDS Screen, Blood (Forensic)			•		•			
54008B	Propoxyphene and Metabolite Confirmation (DUID/DRE), Blood				•				
50018B	Propoxyphene and Metabolite Confirmation, Blood				•				
52463B	Propoxyphene and Metabolite Confirmation, Blood				•				
50018SP	Propoxyphene and Metabolite Confirmation, Serum/Plasma			•	•				
52463SP	Propoxyphene and Metabolite Confirmation, Serum/Plasma			•	•				
3990B	Propoxyphene and Metabolite, Blood				•				
3990SP	Propoxyphene and Metabolite, Serum/Plasma			•	•				



Effective Date:
Monday, January 13, 2020

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
52403B	Strychnine Confirmation, Blood			•	•				
5662B	Strychnine Confirmation, Blood				•				
52403SP	Strychnine Confirmation, Serum/Plasma			•	•				
5662SP	Strychnine Confirmation, Serum/Plasma				•				
52403U	Strychnine Confirmation, Urine			•	•				
5662U	Strychnine Confirmation, Urine				•				
9263B	Strychnine Screen, Blood			•	•				
9263SP	Strychnine Screen, Serum/Plasma			•	•				
9263U	Strychnine Screen, Urine			•	•				



Effective Date:
Monday, January 13, 2020

Test Updates

Test Changes

54151B Brompheniramine Confirmation (DUID/DRE), Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

54150U Brompheniramine Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 2 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 12 month(s)

52245B Brompheniramine Confirmation, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)



Test Updates

Test Changes

5463B Brompheniramine Confirmation, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 3 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

52245SP Brompheniramine Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 3 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 6 month(s)

52245U Brompheniramine Confirmation, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 3 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None



Effective Date:
Monday, January 13, 2020

Test Updates

Test Changes

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 12 month(s)

9118B Brompheniramine Screen, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 5 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

0770B Brompheniramine, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 3 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

0770SP Brompheniramine, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.



Test Updates

Test Changes

Specimen Requirements: 3 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 6 month(s)

0770U Brompheniramine, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 2 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 12 month(s)

54211U Bupivacaine Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: Undetermined
Refrigerated: 7 day(s)
Frozen (-20 °C): Undetermined

52011B Bupivacaine Confirmation, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.



Test Updates

Test Changes

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)

52011SP Bupivacaine Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Stability was changed.

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 6 month(s)

52011U Bupivacaine Confirmation, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: Undetermined
Refrigerated: 7 day(s)
Frozen (-20 °C): Undetermined

0800B Bupivacaine, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.



Test Updates

Test Changes

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)

0800SP Bupivacaine, Serum/Plasma

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Stability was changed.

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 6 month(s)

0800U Bupivacaine, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: Undetermined
Refrigerated: 7 day(s)
Frozen (-20 °C): Undetermined

8152B DUID/DRE Expanded Drug Screen Add-On ProofPOSITIVE®, Blood (Forensic)

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Scope of Analysis was changed.
Gabapentin was added.
BZP and TFMPP were removed.



Test Updates

Test Changes

- Specimen Requirements: 10 mL Blood
 Transport Temperature: Frozen
 Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: Peak serum levels are recommended when monitoring patients because the level in the blood drops so rapidly that many negative results are found at the trough. The peak occurs at 40 to 90 minutes post dose.
 Rejection Criteria: Received Room Temperature. Received Refrigerated. Glass container.
 Stability: Room Temperature: Not Stable
 Refrigerated: Not Stable
 Frozen (-20 °C): 7 day(s)

If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory.

NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

- Scope of Analysis: ELISA (80307): Gabapentin
 Method (CPT Code) LC/TOF-MS (80307): 2-Furanylfentanyl, 7-Amino Flunitrazepam, 9-Hydroxyrisperidone, 10-Hydroxycarbazepine, Acryl Fentanyl, Alfentanil, Amitriptyline, Amoxapine, Aripiprazole, Brompheniramine, Bupropion, Buspirone, Butylone, Butyrylfentanyl, Caffeine, Carbamazepine, Carbamazepine-10,11-Epoxy, Carfentanil, Chlorpheniramine, Chlorpromazine, cis-3-Methylfentanyl, Citalopram / Escitalopram, Clomipramine, Clonazepam, Clonidine, Clozapine, Cyclobenzaprine, Cyclopropylfentanyl, Delorazepam, Desipramine, Desmethylclomipramine, Desmethyldoxepin, Desmethylsertraline, Desmethyltrimipramine, Dextro / Levo Methorphan, Dextrophan / Levorphanol, Dicyclomine, Dibutylone, Diclazepam, Diltiazem, Diphenhydramine, Doxepin, Doxylamine, Duloxetine, Etizolam, Eszopiclone / Zopiclone, Flubromazolam, Flunitrazepam, Fluoxetine, Fluphenazine, Fluvoxamine, Haloperidol, Hydroxybupropion, Hydroxyzine, Iloperidone, Imipramine, Isobutyrylfentanyl, Ketamine, Lamotrigine, Levetiracetam, Loxapine, LSD, Maprotiline, mCPP, Meperidine, Mescaline, Mesoridazine, Metaxalone, Methaqualone, Methocarbamol, Methoxyacetylfentanyl, Methylphenidate, Mexiletine, Mirtazapine, Mitragynine, Norclozapine, Norflunitrazepam, Norfluoxetine, Norketamine, Normeperidine, Norpropoxyphene, Nortriptyline, N-Ethyl Pentylone, O-Desmethylvenlafaxine, Olanzapine, para-Fluorobutyrylfentanyl, para-Fluoroisobutyrylfentanyl, Paroxetine, Perphenazine, Phenazepam, Pheniramine, Phenytoin, Primidone, Promazine, Promethazine, Propoxyphene, Psilocin, Quetiapine, Risperidone, Sertraline, Sufentanil, Tapentadol, Thioridazine, Topiramate, trans-3-Methylfentanyl, Trazodone, Trifluoperazine, Trihexyphenidyl, Trimipramine, U-47700, Valeryl Fentanyl, Venlafaxine, Verapamil, Xylazine, Zaleplon, Ziprasidone, Zonisamide, Scope Statement

Compound Name	Units	Reference Comment
Gabapentin	mcg/mL	

8075U DUID/DRE Expanded Drug Screen Add-On, Urine (Forensic)



Effective Date:

Monday, January 13, 2020

Test Updates

Test Changes

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Salvinorin B was removed.

Specimen Requirements: 6 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Glass container.
Scope of Analysis: LC/TOF-MS (80307): 2-Furanylfentanyl, 7-Amino Flunitrazepam, 9-Hydroxyrisperidone, 10-Hydroxycarbazepine, Acryl Fentanyl, Alfentanil, Amitriptyline, Amoxapine, Atomoxetine, Buprenorphine, Benztropine, Bupropion, Butorphanol, Brompheniramine, Bupivacaine, Butylone, Butyrylfentanyl, Buspirone, BZP, Caffeine, Carbamazepine, Carfentanil, Carbamazepine-10,11-Epoxy, Carisoprodol, cis-3-Methylfentanyl, Chlorpheniramine, Chlorpromazine, Citalopram / Escitalopram, Clomipramine, Clonidine, Clonazepam, Clozapine, Cyclobenzaprine, Cyclopropylfentanyl, Delorazepam, Desipramine, Desmethylclomipramine, Desmethyldoxepin, Desmethyltrimipramine, Dextro / Levo Methorphan, Dextrophan / Levorphanol, Dibutylone, Diclazepam, Dicyclomine, Diltiazem, Diphenhydramine, Donepezil, Doxepin, Doxylamine, Eszopiclone / Zopiclone, Etizolam, Fentanyl, Flecainide, Flubromazolam, Flunitrazepam, Fluoxetine, Fluvoxamine, Guaifenesin, Hydroxybupropion, Hydroxyzine, Imipramine, Isobutyrylfentanyl, Ketamine, Lacosamide, Lamotrigine, Levetiracetam, LSD, Maprotiline, mCPP, Memantine, Meperidine, Meprobamate, Mescaline, Mesoridazine, Metaxalone, Methaqualone, Methoxyacetylfentanyl, Methylphenidate, Mexiletine, Mirtazapine, Mitragynine, Nalbuphine, Norbuprenorphine - Total, Norclozapine, Norfentanyl, Norflunitrazepam, Norfluoxetine, Norketamine, Normeperidine, Nortriptyline, N-Ethyl Pentylone, O-Desmethyltramadol, O-Desmethylvenlafaxine, Olanzapine, Orphenadrine, para-Fluorobutyrylfentanyl, para-Fluoroisobutyrylfentanyl, Paroxetine, Phenazepam, Pheniramine, Promazine, Promethazine, Psilocin, Quetiapine, Quinidine, Risperidone, Sertraline, Sildenafil, Sufentanil, Tapentadol, Tetrahydrozoline, TFMPP, Theophylline, Thioridazine, Tiletamine, Topiramate, Tramadol, trans-3-Methylfentanyl, Trazodone, Trihexyphenidyl, Trimipramine, Valeryl Fentanyl, Triprolidine, Venlafaxine, Verapamil, Xylazine, Yohimbine, Zaleplon, Zolazepam, Zolpidem, Zonisamide, Scope Statement

52493U Designer Benzodiazepines Confirmation (Qualitative), Urine

Summary of Changes: Test Name was changed.
Scope of Analysis was changed.
Bromazepam and Flubromazepam were added.

Scope of Analysis: LC-MS/MS (80346): Bromazepam, Clonazepam, Flubromazolam, Etizolam,
Method (CPT Code) Flubromazepam, Delorazepam, Diclazepam



Effective Date:
Monday, January 13, 2020

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	Bromazepam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries.
Flubromazepam	ng/mL	Flubromazepam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.

52493B Designer Benzodiazepines Confirmation, Blood

Summary of Changes: Scope of Analysis was changed.
Bromazepam and Flubromazepam were added.

Scope of Analysis: LC-MS/MS (80346): Bromazepam, Clonazepam, Flubromazepam, Etizolam,
Method (CPT Code) Flubromazepam, Delorazepam, Diclazepam

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	<p>Bromazepam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries.</p> <p>Average peak plasma concentrations following a single 3 mg, 6 mg and 12 mg dose were reported to be 10 ng/mL at 8 hours, 83 ng/mL at 2 hours and 130 ng/mL at 1-4 hours after dosing, respectively. Chronic oral administration of 9 mg daily resulted in an steady-state plasma concentrations of 81-150 ng/mL (Average = 120 ng/mL). Reported half-lives are 12 - 27 hours.</p> <p>The blood to serum/plasma ratio is not known.</p>



Effective Date:
Monday, January 13, 2020

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Flubromazepam	ng/mL	<p>Flubromazepam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.</p> <p>The peak serum concentration following a single 4 mg oral dose was reported to be 78 ng/mL at 6 hours and the half-life was reported to be 106 hours.</p> <p>The blood to serum/plasma ratio is not known.</p> <p>Substance(s) known to interfere with the identity and/or quantity of the reported result: Chlordiazepoxide, Midazolam.</p>

52493SP Designer Benzodiazepines Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.
Scope of Analysis was changed.
Bromazepam and Flubromazepam were added.

Stability: Room Temperature: Not Stable
Refrigerated: 2 day(s)
Frozen (-20 °C): 14 day(s)

Scope of Analysis: LC-MS/MS (80346): Bromazepam, Clonazepam, Flubromazepam, Etizolam,
Method (CPT Code) Flubromazepam, Delorazepam, Diclazepam

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	<p>Bromazepam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries.</p> <p>Average peak plasma concentrations following a single 3 mg, 6 mg and 12 mg dose were reported to be 10 ng/mL at 8 hours, 83 ng/mL at 2 hours and 130 ng/mL at 1-4 hours after dosing, respectively.</p>



Test Updates

Test Changes

Compound Name	Units	Reference Comment
		Chronic oral administration of 9 mg daily resulted in an steady-state plasma concentrations of 81-150 ng/mL (Average = 120 ng/mL). Reported half-lives are 12 - 27 hours.
		The blood to serum/plasma ratio is not known.
Flubromazepam	ng/mL	Flubromazepam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.
		The peak serum concentration following a single 4 mg oral dose was reported to be 78 ng/mL at 6 hours and the half-life was reported to be 106 hours.
		The blood to serum/plasma ratio is not known.
		Substance(s) known to interfere with the identity and/or quantity of the reported result: Chlordiazepoxide, Midazolam.

54173B Doxylamine Confirmation (DUID/DRE), Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 2 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Stability: Room Temperature: 30 day(s)
 Refrigerated: 30 day(s)
 Frozen (-20 °C): 30 day(s)

54171U Doxylamine Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.



Test Updates

Test Changes

Specimen Requirements: 2 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 12 month(s)

52285B Doxylamine Confirmation, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

5510B Doxylamine Confirmation, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 3 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

52285SP Doxylamine Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.



Test Updates

Test Changes

Specimen Requirements: 3 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 6 month(s)

5510SP Doxylamine Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.

Specimen Requirements: 3 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 6 month(s)

52285U Doxylamine Confirmation, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 3 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None



Test Updates

Test Changes

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 12 month(s)

9163B Doxylamine Screen, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 5 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

9163SP Doxylamine Screen, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.

Specimen Requirements: 5 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 6 month(s)

1817B Doxylamine, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.



Test Updates

Test Changes

Specimen Requirements: 3 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

1817SP Doxylamine, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.

Specimen Requirements: 3 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 6 month(s)

1817U Doxylamine, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 2 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 12 month(s)



Effective Date:
Monday, January 13, 2020

Test Updates

Test Changes

8098B Drug Screen (GC/MS), Blood

Summary of Changes: Scope of Analysis was changed.
Benzocaine was removed.

Scope of Analysis:
Method (CPT Code)

8098SP Drug Screen (GC/MS), Serum/Plasma

Summary of Changes: Specimen Requirements (Special Handling) were changed.
Scope of Analysis was changed.
Benzocaine was removed.

Specimen Requirements: 10 mL Serum or Plasma

Transport Temperature: Refrigerated

Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA),
Plastic container (preservative-free)

Light Protection: Yes

Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Peak serum levels are recommended when monitoring patients because the level in
the blood drops so rapidly that many negative results are found at the trough. The
peak occurs at 40 to 90 minutes post dose. Promptly centrifuge and separate Serum
or Plasma into a plastic screw capped vial using approved guidelines.

Rejection Criteria: Not received Light Protected. Polymer gel separation tube (SST or PST).

Scope of Analysis:
Method (CPT Code)

8098U Drug Screen (GC/MS), Urine

Summary of Changes: Specimen Requirements were changed.
Scope of Analysis was changed.
Benzocaine was removed.

Specimen Requirements: 8 mL Urine

Transport Temperature: Refrigerated

Specimen Container: Plastic container (preservative-free)

Light Protection: Yes

Special Handling: None

Rejection Criteria: Not received Light Protected.

Scope of Analysis:
Method (CPT Code)

1876B Drug Screen - Expanded, Blood



Test Updates

Test Changes

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Scope of Analysis was changed.
Bromazepam, Flubromazepam and Metoprolol were added.
Etomidate, Monoethylglycinexylidide (MEGX), Salvinorin B, Tiletamine,
Triprolidine and Zolazepam were removed.

Specimen Requirements: 10 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Collect sample using alcohol free skin preparation.
Rejection Criteria: Received Room Temperature. Glass container.
Stability: Room Temperature: Not Stable
Refrigerated: Not Stable
Frozen (-20 °C): Undetermined

If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory.

NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	

1876FL Drug Screen - Expanded, Fluid

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Scope of Analysis was changed.
Opiates, Salicylates, Cocaine / Metabolites, Benzodiazepines, Cannabinoids,
Oxycodone / Oxymorphone and Buprenorphine / Metabolite were added.
Methods/CPT Codes were changed [Colorimetry (80307), ELISA (80307)]
Etomidate, Monoethylglycinexylidide (MEGX), Tiletamine and Zolazepam
were removed.



Test Updates

Test Changes

Specimen Requirements: 10 mL Fluid
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Scope of Analysis:
 Method (CPT Code)

Compound Name	Units	Reference Comment
Opiates	ng/mL	
Salicylates	mcg/mL	
Cocaine / Metabolites	ng/mL	
Benzodiazepines	ng/mL	
Cannabinoids	ng/mL	
Oxycodone / Oxymorphone	ng/mL	
Buprenorphine / Metabolite	ng/mL	

1876SP Drug Screen - Expanded, Serum/Plasma

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
 Specimen Requirements (Light Protection) were changed.
 Specimen Requirements (Rejection Criteria) were changed.
 Stability was changed.
 Scope of Analysis was changed.
 Bromazepam, Flubromazepam and Metoprolol were added.
 Benzocaine, Etomidate, Monoethylglycinexylidide (MEGX), Nifedipine,
 Salvinorin B, Tiletamine, Triprolidine and Zolazepam were removed.

Specimen Requirements: 10 mL Serum or Plasma
 Transport Temperature: Frozen
 Specimen Container: Lavender top tube (EDTA), Plastic container (preservative-free), Red top tube (no additive)
 Light Protection: Not Required
 Special Handling: Serum: Collect sample in Red top tube
 Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate). Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Received Room Temperature. Received Refrigerated. Glass container. Polymer gel separation tube (PST). Polymer gel separation tube (SST or PST).
 Stability: Room Temperature: Not Stable
 Refrigerated: Not Stable
 Frozen (-20 °C): 14 day(s)

 Duloxetine in Serum/Plasma requires light protection when submitted at Room Temperature.



Test Updates

Test Changes

If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory.

NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	

1876U Drug Screen - Expanded, Urine

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Scope of Analysis was changed.
Metoprolol, Bromazepam and Flubromazepam were added.
Benzocaine, Monoethylglycinexylidide (MEGX), Salvinorin B, Tiletamine, Triprolidine and Zolazepam were removed.

Specimen Requirements: 12 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Glass container.
Stability: Room Temperature: Undetermined
Refrigerated: Not Stable
Frozen (-20 °C): Undetermined

If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory.

NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

Scope of Analysis:
Method (CPT Code)



Effective Date:
Monday, January 13, 2020

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	

90023B Expanded Drug Screen (DUID/DRE), Blood (Forensic) (CSA)

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Specimen Requirements: 10 mL Blood

Transport Temperature: Frozen

Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)

Light Protection: Not Required

Special Handling: Peak serum levels are recommended when monitoring patients because the level in the blood drops so rapidly that many negative results are found at the trough. The peak occurs at 40 to 90 minutes post dose.

Rejection Criteria: Received Room Temperature. Received Refrigerated. Glass container.

1860B GC/MS Drug Screen (Acid/Neutral), Blood (Forensic)

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 8 mL Blood

Transport Temperature: Refrigerated

Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)

Light Protection: Not Required

Special Handling: None

Rejection Criteria: None

10053U GC/MS Drug Screen, Urine (CSA)

Summary of Changes: Specimen Requirements were changed.
Scope of Analysis was changed.
Benzocaine was removed.



Test Updates

Test Changes

Specimen Requirements: 3 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Yes
Special Handling: None
Rejection Criteria: Not received Light Protected.
Scope of Analysis:
Method (CPT Code)

8758B Hallucinogens Screen, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Specimen Requirements: 5 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Received Room Temperature. Glass container.

8758SP Hallucinogens Screen, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Specimen Requirements: 5 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Glass containers are not acceptable. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Glass container. Polymer gel separation tube (SST or PST).

8758U Hallucinogens Screen, Urine

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.



Test Updates

Test Changes

Specimen Requirements: 6 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Received Room Temperature. Glass container.

54010B LSD Confirmation (DUID/DRE), Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Glass container.

54010U LSD Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 2 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Received Room Temperature. Glass container.
Stability: Room Temperature: 1 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

52065B LSD Confirmation, Blood

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.



Test Updates

Test Changes

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Glass container.

5811B LSD Confirmation, Blood

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Glass container.

52065SP LSD Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 2 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Glass containers are not acceptable. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Glass container. Polymer gel separation tube (SST or PST).
Stability: Room Temperature: Not Stable
Refrigerated: 30 day(s)
Frozen (-20 °C): 24 month(s)

5811SP LSD Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.



Test Updates

Test Changes

Specimen Requirements: 2 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Glass containers are not acceptable. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Glass container. Polymer gel separation tube (SST or PST).
Stability: Room Temperature: Not Stable
Refrigerated: 30 day(s)
Frozen (-20 °C): 24 month(s)

52065U LSD Confirmation, Urine

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Received Room Temperature. Glass container.
Stability: Room Temperature: 1 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

5811U LSD Confirmation, Urine

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Received Room Temperature. Glass container.
Stability: Room Temperature: 1 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)



Effective Date:
Monday, January 13, 2020

Test Updates

Test Changes

2541B LSD Screen, Blood

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Glass container.

2541SP LSD Screen, Serum/Plasma

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 3 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Glass containers are not acceptable. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Glass container. Polymer gel separation tube (SST or PST).
Stability: Room Temperature: Not Stable
Refrigerated: 30 day(s)
Frozen (-20 °C): 24 month(s)

2541U LSD Screen, Urine

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 2 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Received Room Temperature. Glass container.



Test Updates

Test Changes

Stability: Room Temperature: 1 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

2540B LSD Trace Analysis, Blood

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Glass container.

2540SP LSD Trace Analysis, Serum/Plasma

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 2 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Glass containers are not acceptable. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Glass container. Polymer gel separation tube (SST or PST).
Stability: Room Temperature: Not Stable
Refrigerated: 30 day(s)
Frozen (-20 °C): 24 month(s)

2540U LSD Trace Analysis, Urine

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.



Test Updates

Test Changes

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Received Room Temperature. Glass container.
Stability: Room Temperature: 1 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

52076B Methocarbamol and Guaifenesin Confirmation, Blood

Summary of Changes: Test Name was changed.
Stability was changed.
Scope of Analysis was changed.
Guaifenesin was added.

Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Scope of Analysis: LC-MS/MS (80369): Guaifenesin, Methocarbamol
Method (CPT Code)

Compound Name	Units	Reference Comment
Guaifenesin	mcg/mL	Following a single 600 mg oral dose: Peak blood concentrations averaged 1.4 mcg/mL at 15 minutes post dose. Half-life in plasma: 3 hours.

52076FL Methocarbamol and Guaifenesin Confirmation, Fluid

Summary of Changes: Test Name was changed.
Scope of Analysis was changed.
Guaifenesin was added.

Scope of Analysis: LC-MS/MS (80369): Guaifenesin, Methocarbamol
Method (CPT Code)

Compound Name	Units	Reference Comment
Guaifenesin	mcg/mL	No reference data available.

52076SP Methocarbamol and Guaifenesin Confirmation, Serum/Plasma

Summary of Changes: Test Name was changed.
Scope of Analysis was changed.
Guaifenesin was added.



Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (80369): Guaifenesin, Methocarbamol
Method (CPT Code)

Compound Name	Units	Reference Comment
Guaifenesin	mcg/mL	Following a single 600 mg oral dose: Peak blood concentrations averaged 1.4 mcg/mL at 15 minutes post dose. Half-life in plasma: 3 hours. The blood to plasma ratio is unknown for this compound.

52076TI Methocarbamol and Guaifenesin Confirmation, Tissue

Summary of Changes: Test Name was changed.
Scope of Analysis was changed.
Guaifenesin was added.

Scope of Analysis: LC-MS/MS (80369): Guaifenesin, Methocarbamol
Method (CPT Code)

Compound Name	Units	Reference Comment
Guaifenesin	mcg/g	No reference data available.

90034B NPS Comprehensive Screen, Blood (CSA) - Public Health

Summary of Changes: Specimen Requirements were changed.
Scope of Analysis was changed.
2C-H and DMA were removed.

Specimen Requirements: 10 mL Blood
Transport Temperature: Frozen
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature. Received Refrigerated.
Scope of Analysis: LC-MS/MS QTRAP (80307): AMB-FUBINACA, ADMB-FUBICA, 4-cyano-CUMYL-BINACA, ADMB-FUBINACA, MMB-FUBICA, 5-fluoro-QU-PINAC, 5-fluoro-MMB-PINACA, MMB-FUBINACA, CUMYL-THPINACA, 5-fluoro-MDMB-PICA, MDMB-FUBICA, 5-fluoro-MDMB-PINACA / 5-fluoro-EMB-PINACA, AMB-CHMINACA, MDMB-FUBINACA / EMB-FUBINACA, NA-FUBIM, 5-fluoro-EDMB-PINACA, ADMB-CHMINACA, MMB-CHMICA, 5-fluoro-NA-PIC, MDMB-CHMICA, MMB-CHMINACA, NA-FUBIC, MDMB-CHMINAC, ADAMANTYL-FUBINACA, MDMB-CHMCZCA
LC/TOF-MS (80307): 2-Furanylfentanyl, 3-Fluorophenmetrazine, 3-MeO-PCP, 4-ANPP, 4-MeO-PCP, 25B-NBOMe, 25C-NBOMe, 25H-NBOMe, 25I-NBOMe, Acetyl Fentanyl, Acryl Fentanyl, alpha-PVP, Bromazepam, Butylone, Butyrylfentanyl, BZP, Carfentanil, cis-3-Methylfentanyl, Clephedrone, Clonazepam, Cyclopropylfentanyl, Delorazepam, Deschloroetizolam, Dibutylone, Diclazepam, Ethylone, Etizolam, Fentanyl, Flubromazepam, Flubromazolam, Isobutyrylfentanyl, MDPV,



Test Updates

Test Changes

Meclonazepam, Mephedrone, meta-Methylmethoxyacetylfentanyl, Methoxetamine, Methoxyacetylfentanyl, Methoxphenidine, Methylone, Mitragynine, MPHP, N-Ethyl Pentylone, Norfentanyl, ortho-Fluorofentanyl, para-Fluorobutyrylfentanyl, para-Fluorofentanyl, para-Fluoroisobutyrylfentanyl, para-Methylmethoxyacetylfentanyl, Pentedrone, Pentylone, Phenazepam, Pyrazolam, TFMPP, THF-F, trans-3-Methylfentanyl, U-47700, U-49900, U-51754, Valeryl Fentanyl
GC/MS (80307): 2C-B, 2C-B-FLY, 2C-C, 2C-E, 2C-I, 2C-P, 2C-T-2, 2C-T-4, 2C-T-7, 3,4-DMMC, 4-MEC, 4-MTA, 5-IAI, 5-MeO-DALT, 5-MeO-DiPT, 5-MeO-DMT, 5-MeO-MiPT, Alpha PBP, Alpha PPP, alpha-PVT, APB, APDB, BDB, Brepheдрone, Cathinone, DBZP, DET, Dimethylone, DMT, DOB, DOM, Ethylamphetamine, Ethylethcathinone, Ethylphenidate, Fluoroamphetamine, Fluoromethamphetamine, MAPB, MBDB, MBZP, MDAI, MDPBP, MDPPP, MeOPP, MeOPPP, Methcathinone, Methedrone, Methiopropamine, Naphyrone, MPBP, PMA, PMMA, Pyrovalerone, Other Findings

90034U NPS Comprehensive Screen, Urine (CSA) - Public Health

Summary of Changes: Scope of Analysis was changed.
2C-H and DMA were removed.

Scope of Analysis: LC-MS/MS (80307): 4-carboxy-AMB-PINACA, 5-fluoro-PICA 3,3-dimethylbutanoic acid, FUBICA 3,3-dimethylbutanoic acid, 5-fluoro-PINAC-ACID, 4-carboxy-CUMYL-BINACA, 5-fluoro-PIC-ACID, FUBIC-ACID, 5-fluoro-PINACA 3-methylbutanoic acid, FUBINACA 3-methylbutanoic acid, 5-fluoro-PINACA 3,3-dimethylbutanoic acid, FUBINACA 3,3-dimethylbutanoic acid, CHMINACA-3-methylbutanoic acid, 4-carboxy-NA-PIM, CHMINACA 3,3-dimethylbutanoic acid, CHMIC-ACID
LC/TOF-MS (80307): 2-Furanylfentanyl, 3-Fluorophenmetrazine, 3-MeO-PCP, 4-ANPP, 4-MeO-PCP, 25B-NBOMe, 25C-NBOMe, 25H-NBOMe, 25I-NBOMe, Acetyl Fentanyl, Acryl Fentanyl, alpha-PVP, Bromazepam, Butylone, Butyrylfentanyl, BZP, Carfentanil, cis-3-Methylfentanyl, Clephedrone, Clonazolam, Cyclopropylfentanyl, Delorazepam, Deschloroetizolam, Dibutylone, Diclazepam, Ethylone, Etizolam, Fentanyl, Flubromazepam, Flubromazolam, Isobutyrylfentanyl, MDPV, Meclonazepam, meta-Methylmethoxyacetylfentanyl, Methoxyacetylfentanyl, Mephedrone, Methoxetamine, Methoxphenidine, Methylone, Mitragynine, MPHP, N-Ethyl Pentylone, Norfentanyl, ortho-Fluorofentanyl, para-Fluorobutyrylfentanyl, para-Fluorofentanyl, para-Fluoroisobutyrylfentanyl, para-Methylmethoxyacetylfentanyl, Pentedrone, Pentylone, Phenazepam, Pyrazolam, THF-F, TFMPP, trans-3-Methylfentanyl, U-47700, U-49900, U-51754, Valeryl Fentanyl
GC/MS (80307): 2C-B-FLY, 2C-B, 2C-C, 2C-E, 2C-I, 2C-P, 2C-T-2, 2C-T-4, 2C-T-7, 3,4-DMMC, 4-MEC, 4-MTA, 5-IAI, 5-MeO-DALT, 5-MeO-DiPT, 5-MeO-DMT, 5-MeO-MiPT, Alpha PBP, Alpha PPP, alpha-PVT, APB, APDB, BDB, Brepheдрone, Cathinone, DBZP, DET, Dimethylone, DMT, DOB, DOM, Ethylamphetamine, Ethylethcathinone, Ethylphenidate, Fluoroamphetamine, Fluoromethamphetamine, MAPB, MBDB, MBZP, MDAI, MDPBP, MDPPP, MeOPP, MeOPPP, Methcathinone, Methedrone, Methiopropamine, MPBP, Naphyrone, PMA, PMMA, Pyrovalerone, Other Findings

52088FL Nifedipine Confirmation, Fluid

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.



Test Updates

Test Changes

Specimen Requirements: 3 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

52088TI Nifedipine Confirmation, Tissue

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Specimen Requirements: 10 g Tissue
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

8210B Novel Psychoactive Substances (NPS) Screen 2, Blood

Summary of Changes: Scope of Analysis was changed.
2C-H and DMA were removed.

Scope of Analysis: GC/MS (80307): 2C-B, 2C-B-FLY, 2C-C, 2C-E, 2C-I, 2C-P, 2C-T-2, 2C-T-4, 2C-T-7,
Method (CPT Code) 3,4-DMMC, 4-MEC, 4-MTA, 5-IAI, 5-MeO-DALT, 5-MeO-DiPT, 5-MeO-DMT, 5-MeO-MiPT, Alpha PBP, Alpha PPP, alpha-PVT, APB, APDB, BDB, Bredhedrone, Cathinone, DBZP, DET, Dimethylone, DMT, DOB, DOM, Ethylamphetamine, Ethylethcathinone, Ethylphenidate, Fluoroamphetamine, Fluoromethamphetamine, MAPB, MBDB, MBZP, MDAI, MDPBP, MDPPP, MeOPP, MeOPPP, Methcathinone, Methedrone, Methiopropamine, Naphyrone, MPBP, PMA, PMMA, Pyrovalerone, Other Findings

8210SP Novel Psychoactive Substances (NPS) Screen 2, Serum/Plasma

Summary of Changes: Scope of Analysis was changed.
2C-H and DMA were removed.

Scope of Analysis: GC/MS (80307): 2C-B, 2C-B-FLY, 2C-C, 2C-E, 2C-I, 2C-P, 2C-T-2, 2C-T-4, 2C-T-7,
Method (CPT Code) 3,4-DMMC, 4-MEC, 4-MTA, 5-IAI, 5-MeO-DALT, 5-MeO-DiPT, 5-MeO-DMT, 5-MeO-MiPT, Alpha PBP, Alpha PPP, alpha-PVT, APB, APDB, BDB, Bredhedrone, Cathinone, DBZP, DET, Dimethylone, DMT, DOB, DOM, Ethylamphetamine, Ethylethcathinone, Ethylphenidate, Fluoroamphetamine, Fluoromethamphetamine, MAPB, MBDB, MBZP, MDAI, MDPBP, MDPPP, MeOPP, MeOPPP, Methcathinone, Methedrone, Methiopropamine, Naphyrone, MPBP, PMA, PMMA, Pyrovalerone, Other Findings



Test Updates

Test Changes

8210U Novel Psychoactive Substances (NPS) Screen 2, Urine

Summary of Changes: Scope of Analysis was changed.
2C-H and DMA were removed.

Scope of Analysis: GC/MS (80307): 2C-B-FLY, 2C-B, 2C-C, 2C-E, 2C-I, 2C-P, 2C-T-2, 2C-T-4, 2C-T-7,
Method (CPT Code) 3,4-DMMC, 4-MEC, 4-MTA, 5-IAI, 5-MeO-DALT, 5-MeO-DIPT, 5-MeO-DMT, 5-MeO-MiPT, Alpha PBP, Alpha PPP, alpha-PVT, APB, APDB, BDB, Bredhedrone, Cathinone, DBZP, DET, Dimethylone, DMT, DOB, DOM, Ethylamphetamine, Ethylethcathinone, Ethylphenidate, Fluoroamphetamine, Fluoromethamphetamine, MAPB, MBDB, MBZP, MDAI, MDPBP, MDPPP, MeOPP, MeOPPP, Methcathinone, Methedrone, Methiopropamine, MPBP, Naphyrone, PMA, PMMA, Pyrovalerone, Other Findings

90000U Opiates Screen, Urine (CSA)

Summary of Changes: Scope of Analysis was changed.
Oxycodone / Oxymorphone was removed.

Scope of Analysis: EIA (80307): Opiates
Method (CPT Code)

52389B Phenethylamines Confirmation 2 (Qualitative), Blood

Summary of Changes: Stability was changed.
Scope of Analysis was changed.
DMA and 2C-H were removed.

Stability: Room Temperature: 3 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Scope of Analysis: LC-MS/MS (80371): PMA, Cathinone, Methcathinone, 5-MeO-DMT, DMT,
Method (CPT Code) Methedrone, DET

52389SP Phenethylamines Confirmation 2 (Qualitative), Serum/Plasma

Summary of Changes: Scope of Analysis was changed.
DMA and 2C-H were removed.

Scope of Analysis: LC-MS/MS (80371): PMA, Cathinone, Methcathinone, 5-MeO-DMT, DMT,
Method (CPT Code) Methedrone, DET

52389U Phenethylamines Confirmation 2 (Qualitative), Urine

Summary of Changes: Scope of Analysis was changed.
DMA and 2C-H were removed.

Scope of Analysis: LC-MS/MS (80371): PMA, Cathinone, Methcathinone, 5-MeO-DMT, DMT,
Method (CPT Code) Methedrone, DET

54182B Pheniramine Confirmation (DUID/DRE), Blood



Test Updates

Test Changes

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

54181U Pheniramine Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 2 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 12 month(s)

52291B Pheniramine Confirmation, Blood

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

52291SP Pheniramine Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 3 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 6 month(s)



Test Updates

Test Changes

52291U Pheniramine Confirmation, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.

Specimen Requirements: 3 mL Urine
 Transport Temperature: Refrigerated
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: None
 Stability: Room Temperature: 30 day(s)
 Refrigerated: 30 day(s)
 Frozen (-20 °C): 12 month(s)

3560B Pheniramine, Blood

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)
 Refrigerated: 30 day(s)
 Frozen (-20 °C): 30 day(s)

8063B Postmortem, Basic to Expanded Upgrade, Blood (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
 Specimen Requirements (Rejection Criteria) were changed.
 Scope of Analysis was changed.
 Bromazepam, Flubromazepam and Metoprolol were added.
 Salvinorin B was removed.

Specimen Requirements: 10 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: Peak sample should be drawn 60 minutes after an intramuscular injection, 30 minutes after the end of a 30 minute intravenous infusion. Trough sample should be drawn immediately prior to next dose. Promptly centrifuge and separate Serum into a plastic screw capped vial using approved guidelines.
 Rejection Criteria: Glass container.
 Scope of Analysis:
 Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	
Flubromazepam	ng/mL	



Effective Date:
Monday, January 13, 2020

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Metoprolol	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.

8063FL Postmortem, Basic to Expanded Upgrade, Fluid (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Specimen Requirements: 10 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

8063SP Postmortem, Basic to Expanded Upgrade, Serum/Plasma (Forensic)

Summary of Changes: Scope of Analysis was changed.
Bromazepam, Flubromazepam and Metoprolol were added.
Benzocaine and Salvinorin B were removed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	

8063TI Postmortem, Basic to Expanded Upgrade, Tissue (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Specimen Requirements: 10 g Tissue
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None



Test Updates

Test Changes

8063U Postmortem, Basic to Expanded Upgrade, Urine (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Bromazepam, Flubromazepam and Metoprolol were added.
Benzocaine and Salvinorin B were removed.

Specimen Requirements: 7 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Glass container.
Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	

10052B Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Metoprolol, Bromazepam and Flubromazepam were added.
Salvinorin B was removed.

Specimen Requirements: 10 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: In addition to blood, collect 1 mL of Vitreous fluid for the Alcohol Confirmation.
Collect sample using alcohol free skin preparation.
Rejection Criteria: Glass container.
Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	
Flubromazepam	ng/mL	



Test Updates

Test Changes

Compound Name	Units	Reference Comment
Metoprolol	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.

8042B Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
 Specimen Requirements (Rejection Criteria) were changed.
 Scope of Analysis was changed.
 Bromazepam, Flubromazepam and Metoprolol were added.
 Salvinorin B was removed.

Specimen Requirements: 10 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: In addition to blood, collect 1 mL of Vitreous fluid for the Alcohol Confirmation.
 Collect sample using alcohol free skin preparation.
 Rejection Criteria: Glass container.
 Scope of Analysis:
 Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	

8057B Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood - University of MI (CSA)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
 Specimen Requirements (Rejection Criteria) were changed.
 Scope of Analysis was changed.
 Bromazepam, Flubromazepam and Metoprolol were added.
 Salvinorin B was removed.

Specimen Requirements: 10 mL Blood
 Transport Temperature: Refrigerated
 Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
 Light Protection: Not Required
 Special Handling: Collect sample using alcohol free skin preparation.
 Rejection Criteria: Glass container.



Effective Date:
Monday, January 13, 2020

Test Updates

Test Changes

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	

8062B Postmortem, Expanded w/o Alcohol, Blood (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Bromazepam, Flubromazepam and Metoprolol were added.
Salvinorin B was removed.

Specimen Requirements: 10 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Submit with Chain of Custody.
Ensure that container remains tightly sealed.
Rejection Criteria: Glass container.
Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	

8062FL Postmortem, Expanded w/o Alcohol, Fluid (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.



Test Updates

Test Changes

Specimen Requirements: 10 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

8062TI Postmortem, Expanded w/o Alcohol, Tissue (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Specimen Requirements: 10 g Tissue
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

8062U Postmortem, Expanded w/o Alcohol, Urine (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Bromazepam, Flubromazepam and Metoprolol were added.
Benzocaine and Salvinorin B were removed.

Specimen Requirements: 12 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Glass container.
Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	



Test Updates

Test Changes

8054B Postmortem, Expanded with NPS, Blood

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Amlodipine, Hydroxychloroquine and Metoprolol were added.

Specimen Requirements: 10 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Collect sample using alcohol free skin preparation.
Rejection Criteria: Glass container.
Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Amlodipine	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Hydroxychloroquine	ng/mL	
Metoprolol	ng/mL	

90025B Postmortem, Expanded, Blood (Forensic) (CSA)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Bromazepam, Flubromazepam and Metoprolol were added.
Salvinorin B was removed.

Specimen Requirements: 10 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Collect sample using alcohol free skin preparation.
Rejection Criteria: Glass container.
Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	
Flubromazepam	ng/mL	



Test Updates

Test Changes

Compound Name	Units	Reference Comment
Metoprolol	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.

8052B Postmortem, Expanded, Blood (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Bromazepam, Flubromazepam and Metoprolol were added.
Salvinorin B was removed.

Specimen Requirements: 10 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Collect sample using alcohol free skin preparation.
Rejection Criteria: Glass container.
Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	

8052FL Postmortem, Expanded, Fluid (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Specimen Requirements: 10 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

8052SP Postmortem, Expanded, Serum/Plasma (Forensic)



Test Updates

Test Changes

Summary of Changes: Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Metoprolol, Bromazepam and Flubromazepam were added.
Benzocaine and Salvinorin B were removed.

Specimen Requirements: 10 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA), Plastic container (preservative-free), Red top tube (no additive)
Light Protection: Yes
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate).
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Not received Light Protected. Glass container. Polymer gel separation tube (PST).
Polymer gel separation tube (SST or PST).
Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	
Flubromazepam	ng/mL	
Metoprolol	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.

8052TI Postmortem, Expanded, Tissue (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.

Specimen Requirements: 10 g Tissue
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

8052U Postmortem, Expanded, Urine (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Flubromazepam, Metoprolol and Bromazepam were added.
Benzocaine and Salvinorin B were removed.



Effective Date:
Monday, January 13, 2020

Test Updates

Test Changes

Specimen Requirements: 10 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Glass container.
Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	

39052B Postmortem, Expanded-II, Blood (Forensic) (SSA)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Metoprolol, Bromazepam and Flubromazepam were added.
Salvinorin B was removed.

Specimen Requirements: 10 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Collect sample using alcohol free skin preparation.
Rejection Criteria: Glass container.
Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	

39042B Postmortem, Expanded-II, with Vitreous Alcohol Confirmation, Blood (Forensic) (SSA)



Test Updates

Test Changes

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Flubromazepam, Metoprolol and Bromazepam were added.
Salvinorin B was removed.

Specimen Requirements: 10 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Collect sample using alcohol free skin preparation.
Rejection Criteria: Glass container.
Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	

10092B Postmortem, Expert w/Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)

Summary of Changes: Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Methods/CPT Codes were changed [LC-MS/MS QTRAP (80307), LC/TOF-MS (80307)]
The entire Test Scope was updated.

Specimen Requirements: 10 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: In addition to blood, collect 1 mL of Vitreous fluid for the Alcohol Confirmation.
Collect sample using alcohol free skin preparation.
Rejection Criteria: Glass container.
Scope of Analysis:
Method (CPT Code)

10151B Postmortem, Expert w/Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)



Test Updates

Test Changes

Summary of Changes: Scope of Analysis was changed.
Order of Reporting was changed.
Methods/CPT Codes were changed [LC-MS/MS QTRAP (80307), LC/TOF-MS (80307)]
The entire Test Scope was updated.

Scope of Analysis:
Method (CPT Code)

8092B Postmortem, Expert, Blood (Forensic)

Summary of Changes: Scope of Analysis was changed.
Benzocaine was removed.

Scope of Analysis:
Method (CPT Code)

4177B Postmortem, SUIDS Screen, Blood (Forensic)

Summary of Changes: Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Scope of Analysis was changed.
Bromazepam, Flubromazepam and Metoprolol were added.
Salvinorin B was removed.

Specimen Requirements: 10 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Submit with Chain of Custody.
Collect sample using alcohol free skin preparation.
Rejection Criteria: Glass container.
Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Bromazepam	ng/mL	The reported qualitative result for this substance was based upon a single analysis only. If confirmation testing is required please contact the laboratory.
Flubromazepam	ng/mL	
Metoprolol	ng/mL	

54008B Propoxyphene and Metabolite Confirmation (DUID/DRE), Blood

Summary of Changes: Stability was changed.



Test Updates

Test Changes

Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 3 month(s)

50018B Propoxyphene and Metabolite Confirmation, Blood

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 3 month(s)

52463B Propoxyphene and Metabolite Confirmation, Blood

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 3 month(s)

50018SP Propoxyphene and Metabolite Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Stability was changed.

Specimen Requirements: 2 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 3 month(s)

52463SP Propoxyphene and Metabolite Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Stability was changed.

Specimen Requirements: 2 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).



Test Updates

Test Changes

Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 3 month(s)

3990B Propoxyphene and Metabolite, Blood

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 3 month(s)

3990SP Propoxyphene and Metabolite, Serum/Plasma

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Stability was changed.

Specimen Requirements: 2 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 14 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 3 month(s)

52403B Strychnine Confirmation, Blood

Summary of Changes: Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 5 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 11 month(s)

5662B Strychnine Confirmation, Blood

Summary of Changes: Stability was changed.



Effective Date:
Monday, January 13, 2020

Test Updates

Test Changes

Stability: Room Temperature: 2 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 11 month(s)

52403SP Strychnine Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 5 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 2 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 11 month(s)

5662SP Strychnine Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 2 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 11 month(s)

52403U Strychnine Confirmation, Urine

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 3 mL Urine
Transport Temperature: Frozen
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature. Received Refrigerated.
Stability: Room Temperature: 1 day(s)
Refrigerated: 1 day(s)
Frozen (-20 °C): 3 month(s)

5662U Strychnine Confirmation, Urine



Test Updates

Test Changes

Summary of Changes: Stability was changed.

Stability: Room Temperature: 1 day(s)
Refrigerated: 1 day(s)
Frozen (-20 °C): 3 month(s)

9263B Strychnine Screen, Blood

Summary of Changes: Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 7 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 11 month(s)

9263SP Strychnine Screen, Serum/Plasma

Summary of Changes: Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 7 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 2 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 11 month(s)

9263U Strychnine Screen, Urine

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.



Effective Date:

Monday, January 13, 2020

Test Updates

Test Changes

Specimen Requirements: 5 mL Urine
Transport Temperature: Frozen
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature. Received Refrigerated.
Stability: Room Temperature: 1 day(s)
Refrigerated: 1 day(s)
Frozen (-20 °C): 3 month(s)



Effective Date:

Monday, January 13, 2020

Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
10101U	Novel Psychoactive Substances (NPS) (Qualitative), Urine (CSA)	No Alternate Tests Available